Your shopping cart is currently empty

Fasudil mesylate (HA-1077; AT877) is a nonspecific, orally active inhibitor of RhoA/ROCK, exhibiting additional inhibitory effects on protein kinases with a K i of 0.33 μM for ROCK1. It shows IC 50 values of 0.158 μM for ROCK2, and 4.58 μM, 12.30 μM, and 1.650 μM for PKA, PKC, and PKG, respectively. Furthermore, Fasudil mesylate acts as a potent Ca 2+ channel antagonist and vasodilator, enhancing its pharmacological profile [1] [2] [3] [4] [5] [6].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 2-4 weeks | 2-4 weeks | |
| 50 mg | $1,980 | 2-4 weeks | 2-4 weeks | |
| 100 mg | $2,500 | 2-4 weeks | 2-4 weeks |
| Description | Fasudil mesylate (HA-1077; AT877) is a nonspecific, orally active inhibitor of RhoA/ROCK, exhibiting additional inhibitory effects on protein kinases with a K i of 0.33 μM for ROCK1. It shows IC 50 values of 0.158 μM for ROCK2, and 4.58 μM, 12.30 μM, and 1.650 μM for PKA, PKC, and PKG, respectively. Furthermore, Fasudil mesylate acts as a potent Ca 2+ channel antagonist and vasodilator, enhancing its pharmacological profile [1] [2] [3] [4] [5] [6]. |
| Molecular Weight | 387.47 |
| Formula | C15H21N3O5S2 |
| Cas No. | 1001206-62-7 |
| Smiles | S(C)(=O)(=O)O.S(=O)(=O)(C=1C2=C(C=CC1)C=NC=C2)N3CCCNCC3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.